PPT-Audit of EGFR mutation testing in patients with proven Non-

Author : aaron | Published Date : 2017-06-03

On behalf of the North of England Cancer Network Lung NSSG Dr Naomi Chamberlin Dr Ann Ward Aims Overview of brief Method Contributing Trusts Results Discussion Overview

Presentation Embed Code

Download Presentation

Download Presentation The PPT/PDF document "Audit of EGFR mutation testing in patien..." is the property of its rightful owner. Permission is granted to download and print the materials on this website for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.

Audit of EGFR mutation testing in patients with proven Non-: Transcript

On behalf of the North of England Cancer Network Lung NSSG Dr Naomi Chamberlin Dr Ann Ward Aims Overview of brief Method Contributing Trusts Results Discussion Overview of brief To gather data on all patients with a diagnosis of nonsmall cell lung cancer across the Network for whom specimens have been sent for EGFR mutation testing. Park M et al. JASN September 2012. Renal Journal Club Oct 2012 BHH. Matthew Graham-Brown. Introduction. CKD is associated with increased CVS risk and mortality, with an increased incidence of heart failure…….this is well known!!. Jesus. Cabral MD. Alejandro Navas. . MD MSc. Enrique . O.. . Graue-. Hernández. . MD MSc. Arturo Ramirez. -. Miranda. . . MD. Beatriz . Buentello. . Ph. D. Juan Carlos . Zenteno. . Dr David Kennedy. Dr Hugh Rayner. Dr Jessie Raju. Miss Kamaljit Chatha. Chronic kidney disease (CKD). CKD . is common . – est. 9% adults in England.. . Prevalence . increased in older people, those with . Le Chevalier, . MD. The Role of Translational Research . in . NSCLC. Outline of Talk. The importance of translational research in improving treatment of NSCLC. Key remaining unmet needs. Overview of promising approaches/agents in the future treatment of NSCLC . September 6, 2014 | Boston. In ALK, ROS1 & EGFR Lung Cancers. Combinations for Treating EGFR Acquired Resistance. Melissa L. Johnson, MD. Dx. : EGFR+ lung cancer. Acquired Resistance. TKI. s. . and . related. . treatment . strategies. Rafal . Dziadziuszko. Medical. . University. of Gdańsk, Poland. 16th European . Congress. „. Perspectives. in . Lung. Cancer. ” . Torino. Nathan Pennell, M.D., Ph.D.. September 6, 2014. Objectives. Discuss the role of chemotherapy in molecularly defined populations. Discuss the addition of chemo and/or bevacizumab (Avastin) to targeted therapy. Increases . Safety Window in Preclinical Studies. Bryan A. Irving Ph.D. . Vice President, Cancer Immunology @CytomX Therapeutics, Inc.. Presenter Disclosure Information. The following relationships exist related to this presentation:. k. inase . i. nhibition. Danny Rayes . Lung Cancer and Epidermal Growth Factor Receptor. Lung cancer is a leading cause cancer-related death . Two types of lung cancer. Non small cell (NSCLC) 80-85%. from the. Technology of the . Future. into. . the. Technology of the . Present. Paul . Ammann. 2015 Mutation Workshop Keynote. Graz, Austria . April 13, 2015. 1. A Poll. How many of you. Agree?. Disagree?. The types of proteins an organism possesses depend upon the . sequence of nucleotides. The two main types of gene mutations include:. Point mutation: one base pair is replaced for another base pair.. Cécile Jovelet. Postdocoral. . fellow. Translational. . research. . lab. Gustave Roussy Institute, France. Introduction . 12/04/2017. 2. Lung cancer: . third most frequent cancer. Non-Small Cell Lung Cancer (NSCLC): 80% cases of lung cancer. toxicity. ESDO Learning Bytes 2021. Dr Violaine RANDRIAN. Department of Gastroenterology, Poitiers University Hospital, France. DISCLOSURES. AMGEN. MERCK. PHARMAFIELD. BAYER. Anti-EGFR in Gastroenterology. Gregory J. Riely. November 2021. What about those other EGFR mutations?. EGFR. ALK. ROS1. BRAF. RET. MET Exon14. KRAS G12C. EGFR exon 20. ERBB2/HER2. NTRK. Key Subtypes. EGFR exon 20 insertions . ~1% of people with NSCLC.

Download Document

Here is the link to download the presentation.
"Audit of EGFR mutation testing in patients with proven Non-"The content belongs to its owner. You may download and print it for personal use, without modification, and keep all copyright notices. By downloading, you agree to these terms.